DESCRIPTION

Regenerative medicine is the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues.

It also includes the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs.

These approaches can amplify our healing process in the places it is needed, or take over the function of a damaged organ.

Vascularized osteogenesis is essential for successful bone regeneration, yet its realization during large size bone defect healing remains challenging due to the difficulty to couple multiple biological processes.

Herein is constructed to achieve optimized bone morphogenetic protein-2 therapeutic index and provide intrinsic angiogenic induction.

The vECM regulates BMP-2 kinetics to match the bone healing timeframe, but also promotes angiogenesis both in vitro and in vivo.

In vivo results also show that vECM-mediated BMP-2 release remarkably enhances vascularized bone formation for critical size bone defects.

In particular, blood vessel ingrowth stained with CD31 marker in the defect area is substantially encouraged over the course of healing, suggesting incorporation of vECM served roles in both angiogenesis and osteogenesis.

Thus, the authors’ study exemplifies that affinity of growth factor towards ECM may be a promising strategy.

It can lead to develop sophisticated delivery systems endowed with desirable properties for regenerative medicine applications.

Back